Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Rhea-AI Summary
Clearmind Medicine (NASDAQ: CMND) announced publication of a U.S. patent application on Oct 31, 2025 expanding intellectual property coverage for its non‑hallucinogenic neuroplastogen MEAI (5‑methoxy‑2‑aminoindane) for treatment of cocaine addiction.
The filing emphasizes MEAI's proposed mechanism—modulation of serotonin and dopamine pathways—and positions the program against a disorder with no FDA‑approved pharmacological treatments. The release cites a global market estimate of $1.36 billion in 2025 growing to $2.03 billion by 2032, and frames the application as strengthening Clearmind's IP portfolio and pipeline strategy for non‑hallucinogenic neuroplastogens.
Positive
- U.S. patent application published on Oct 31, 2025
- IP coverage expanded for non‑hallucinogenic MEAI
- Global market estimated at $1.36B in 2025
Negative
- Patent is an application, not an issued patent
- No clinical efficacy data for MEAI in cocaine addiction disclosed
- Market projection to $2.03B by 2032 is an estimate, not guaranteed
News Market Reaction – CMND
In the Oct 31 session, CMND declined 12.28%, reflecting a significant negative market reaction. Argus tracked a peak move of +13.4% during that session. Argus tracked a trough of -29.7% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 8.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of cocaine addiction.
The application strengthens Clearmind’s growing intellectual property portfolio and reinforces MEAI’s potential to address a major unmet medical need. Cocaine use disorder affects millions worldwide and currently has no FDA-approved pharmacological treatment. The global market for cocaine addiction treatment is estimated at
MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalable alternative to existing behavioral interventions.
“Securing protection for MEAI’s potential use in cocaine addiction supports our broader strategy to build a robust pipeline of non-hallucinogenic neuroplastogens,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. “We believe this patent filing represents another key step in positioning Clearmind as a leader in next-generation addiction therapeutics.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its growing intellectual property portfolio, MEAI potential to address a major unmet medical need, the growth of the market for the treatment of cocaine use disorder, the Company’s strategy to build a robust pipeline of non-hallucinogenic neuroplastogens and positioning Clearmind as a leader in next-generation addiction therapeutics. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
